期刊文献+

原发性肝癌切除术后预后因素及生存分析 被引量:4

Prognostic and survival analysis of primary liver cancer after hepatectomy
原文传递
导出
摘要 目的探讨影响原发性肝癌切除术后生存时间的因素,为预测预后提供依据。方法回顾性分析接受手术切除的172例原发性肝癌患者的临床资料,采用Kaplain.Meier法计算生存率,用Log.rank检验进行单因素分析,Cox比例风险模型进行多因素分析,最终筛选出对原发性肝癌切除预后有影响的临床病理因素。结果患者的中位生存期为18个月,单因素分析显示:肝功能Child—Pugh分级、肝硬化、肿瘤大小、乙肝病史、甲胎蛋白(AFP)、门静脉癌栓是影响生存率的重要因素(P〈0.05),而多因素分析则提示肝功能Child—Pugh分级、肿瘤大小、AFP、门静脉癌栓是影响肝癌术后预后的重要独立因素(P〈0.05)。结论肝功能Child—Pugh分级、肿瘤大小、AFP、门静脉癌栓是肝癌患者术后预后的独立影响因素。 Objective To explore the factors related to the prognosis and survival duration of primary liver cancer patients after hepatectomy. Methods The data of primary liver cancer patients 'who were treated by surgical resection were analyzed retrospectively. Kaplain-Meier method was used to evaluate survival rates. Log-rank test and Cox regression analysis were used to screen out related clinical phathology factors. Results The median survival time was eighteen months. Univarivate analysis showed that liver function Child-Pugh classification, cirrhosis, tumor size, HBV infection, AFP, portal vein tumor thrombus significantly correlated with survival rates (P 〈 0.05). Multivariate analysis showed that liver function Child-Pugh classification, tumor size, AFP and portal vein tumor thrombus were the independent prognostic factors of primary liver cancer (P 〈 0.05). Conclusion Many factors are related to the prognosis of primary liver cancer after operation. Liver function Child-Pugh classification, tumor size, AFP and portal vein tumor thrombus affect prognostic independently.
出处 《肿瘤研究与临床》 CAS 2013年第9期588-590,共3页 Cancer Research and Clinic
基金 川北医学院苗圃基金(MP-09A-40)
关键词 肝肿瘤 肝切除术 预后因素 生存率 Liver neoplasms Hepatectomy Prognosis factor Survival rate
  • 相关文献

参考文献7

二级参考文献42

共引文献133

同被引文献36

  • 1Wan-Yee Lau,Eric C.H.Lai,Stephanie H.Y.Lau.Methods of vascular control technique during liver resection:a comprehensive review[J].Hepatobiliary & Pancreatic Diseases International,2010,9(5):473-481. 被引量:28
  • 2Shao-QiangLi,Li-JianLiang,Jie-FuHuang,ZhiLi.Ischemic preconditioning protects liver from hepatectomy under hepatic inflow occlusion for hepatocellular carcinoma patients with cirrhosis[J].World Journal of Gastroenterology,2004,10(17):2580-2584. 被引量:20
  • 3Hu Y, Wang S, Wu X, et al. Chinese herbal medicine- derived compounds for cancer therapy:a focus on hepa- tocellular carcinoma [ J ]. J Ethnopharmacol, 2013,149 (3) :601 -612. 被引量:1
  • 4Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain:role of resveratrol in microglial activation [ J ]. Eur J Pharmacol, 2010,636 ( 1/3 ) : 1 - 7. 被引量:1
  • 5Piotrowska H, Kucinska M, Murias M. Biological activity of piceatannol : leaving the shadow of resveratrol [ J ]. Mutat Res ,2012,750( 1 ) :60 - 82. 被引量:1
  • 6Yang XH, Feng ZE, Yan M, et al. XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer [ J ]. PLoS One,2012,7(3 ) :e31 601. 被引量:1
  • 7Huynh C, Hung P, Yang LX. Improved chemotherapy for hepatocellular carcinoma [ J ]. Anticancer Res, 2012,32 (4) :1 379-1 386. 被引量:1
  • 8Carr BI. Hepatocellular carcinoma:current management and future trends [ J ]. Gastroenterology, 2004, 127 ( 5 Suppl 1) :$218 - $224. 被引量:1
  • 9Xu Y, Wang C, Li Z. A new strategy of promoting cispl- atin chemotherapeutic efficiency by targeting endoplas- mic reticulum stress [ J ]. Mol Clin 0ncol,2014,2 ( 1 ) :3 -7,. 被引量:1
  • 10Rezk YA, Balulad SS, Keller RS, et al. Use of resvera- trol to improve the effectiveness of cisplatin and doxoru- bicin. Study in human gynecologic cancer cell lines and in rodent heart [ J ]. Am J Obstet Gynecol, 2006,194, e23 - e26. 被引量:1

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部